Holen Sie sich die Stockscreener-App
18.13
1.17%
0.21
Handel nachbörslich:
18.66
0.53
+2.92%
Schlusskurs vom Vortag:
$17.92
Offen:
$18.37
24-Stunden-Volumen:
3.06M
Relative Volume:
1.27
Marktkapitalisierung:
$2.99B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-446.21M
KGV:
-5.1166
EPS:
-3.5434
Netto-Cashflow:
$-423.92M
1W Leistung:
+2.49%
1M Leistung:
+16.67%
6M Leistung:
+39.57%
1J Leistung:
+50.46%
1-Tages-Spanne:
$18.11
$18.88
1-Wochen-Bereich:
$17.41
$20.03
52-Wochen-Spanne:
$6.36
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
18.13 | 2.96B | 0 | -446.21M | -423.92M | -3.5434 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.10 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.91 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.30 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.91 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
289.65 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Why Dyne Therapeutics Stock Is Surging Higher Now - TipRanks
Braidwell LP Sells 542,868 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case - simplywall.st
Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data - Yahoo Finance
Integral Health Asset Management LLC Buys New Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Dyne Therapeutics Insider Sold Shares Worth $2,530,562, According to a Recent SEC Filing - marketscreener.com
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs - Insider Monkey
WINTON GROUP Ltd Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data - simplywall.st
5 Best Day Trading Stocks to Buy Now - Insider Monkey
Dyne Therapeutics launches phase 3 trial for DM1 treatment By Investing.com - Investing.com Nigeria
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade - Finviz
Brian Posner Purchases 3,000 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock - MarketBeat
Director adds Dyne Therapeutics (DYN) shares in open-market purchase - Stock Titan
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate; Shares Surge 19% - AlphaStreet
Dyne Therapeutics (DYN) Receives a Buy from Guggenheim - The Globe and Mail
Jefferies Maintains Buy on Dyne Therapeutics (DYN) March 2026 - Meyka
Dyne Therapeutics (DYN) Receives Analyst Rating Update from Char - GuruFocus
Dyne Therapeutics (NASDAQ:DYN) Trading 11.2% HigherTime to Buy? - MarketBeat
Baird reiterates Dyne Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Stifel reiterates Dyne Therapeutics stock rating on DMD data By Investing.com - Investing.com Australia
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case (NASDAQ:DYN) - Seeking Alpha
Stifel reiterates Dyne Therapeutics stock rating on trial design By Investing.com - Investing.com Canada
Jones Trading reiterates Buy on Dyne Therapeutics stock after DMD, DM1 updates - Investing.com
Stifel reiterates Dyne Therapeutics stock rating on DMD data - Investing.com South Africa
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) - Sahm
Rate Hike: Will Dyne Therapeutics Inc benefit from government policy2026 EndofMonth & High Win Rate Trade Alerts - baoquankhu1.vn
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy - Investing News Network
Dyne Therapeutics (DYN) Begins Phase 3 Trial for Myotonic Dystro - GuruFocus
Dyne Therapeutics (DYN) Reveals Encouraging Results from Zelecim - GuruFocus
Dyne Therapeutics starts Phase 3 HARMONIA trial for z-basivarsen in DM1 - Traders Union
Dyne Therapeutics launches phase 3 trial for DM1 treatment - Investing.com
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) - Bitget
150-patient Dyne trial focuses on myotonic dystrophy daily function - Stock Titan
Dyne Therapeutics Announces New Positive Cardiopulmonary Results From Deliver Trial Of Z-Rostudirsen In Duchenne Muscular Dystrophy (Dmd) - TradingView
Dyne DMD trial shows better breathing, heart health after 24 months - Stock Titan
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Dyne Therapeutics (DYN) CCO completes small tax-driven share sale - Stock Titan
Dyne Therapeutics (DYN) CMO auto-sells shares to cover RSU tax obligations - Stock Titan
T. Rowe Price (NASDAQ: DYN) lists 26,578,437 shares, a 16.2% stake - Stock Titan
HC Wainwright Predicts Higher Earnings for Dyne Therapeutics - MarketBeat
A Look At Dyne Therapeutics (DYN) Valuation After Q4 2025 Earnings Beat And Ongoing Clinical Progress - Yahoo Finance
FDA curtails Pepgen’s Freedom2 operate in DM1 - bioworld.com
Lifesci Capital Brokers Raise Earnings Estimates for DYN - MarketBeat
Q1 Earnings Estimate for DYN Issued By HC Wainwright - MarketBeat
Rafferty Asset Management LLC Boosts Stake in Dyne Therapeutics, Inc. $DYN - MarketBeat
DYN: Validated platform and pipeline set stage for multiple rare disease launches and growth - TradingView
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.99%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):